Amgen has its $13.4 billion purchase of Celgene's psoriasis blockbuster Otezla in the bag, but will the buy pay off to the extent the company is predicting? Analysts are cautiously optimistic.
privacy policy | terms of use | contact us | advertise | pharma jobs | pharma blogs | facebook | twitter
Copyright © 2024,